Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65. (2016)
Attributed to:
Development of an AAV vector for treatment of inherited retinal dystrophy caused by RPE65 deficiency
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/gt.2016.66
PubMed Identifier: 27653967
Publication URI: http://europepmc.org/abstract/MED/27653967
Type: Journal Article/Review
Volume: 23
Parent Publication: Gene therapy
Issue: 12
ISSN: 0969-7128